Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ICMT | O60725 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435727 | 0.86 | LMNA (0.48) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL8904963 | 0.86 | LMNA (0.48) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL15399522 | 0.85 | CYP2B6 (0.46) | MEN1KMT2ATSHRALDH1A1KDM4E | |
| SCHEMBL5282593 | 0.79 | GAA (0.46) | TSHRALDH1A1LMNASMN1; SMN2MAPT | |
| SCHEMBL11627077 | 0.73 | KCNA5 (0.56) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL9650536 | 0.72 | CYP2B6 (0.46) | TSHRALDH1A1LMNASMN1; SMN2KCNA5 | |
| SCHEMBL20025834 | 0.72 | ICMT (0.43) | MEN1KMT2APKMTSHRAKR1C3 | |
| SCHEMBL5280949 | 0.71 | KCNN4 (0.48) | MEN1KMT2ATSHRAKR1C3ALDH1A1 | |
| SCHEMBL27439222 | 0.71 | SMN1; SMN2 (0.45) | PKMTSHRAKR1C3ALDH1A1LMNA | |
| SCHEMBL20025835 | 0.69 | ICMT (0.36) | MEN1KMT2APKMTSHRAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093960-A1 | METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2018-04-05 | — | — | US | disclosed |
| US-8871507-B2 | Method of inhibiting apolipoprotein-E expression comprising administering a triarylmethyl amine compound | CALIFORNIA STATE UNIVERSITY, FRESNO (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140080209-A1 | METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION COMPRISING ADMINISTERING A TRIARYLMETHYL AMINE COMPOUND | CALIFORNIA STATE UNIVERSITY FRESNO (US) | 2014-03-20 | — | — | US | disclosed |
| US-8633195-B1 | Method of inhibiting apolipoprotein-E expression comprising administering a triarylmethyl amine compound | Fresno California State University (US) | 2014-01-21 | — | — | US | disclosed |
| US-20140005196-A1 | METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION COMPRISING ADMINISTERING A TRIARYLMETHYL AMINE COMPOUND | California State University Fullerton (US) | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093960-A1 | METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND | LDLR, APOB, NR1H2 | MEN1 4593/4885KMT2A 4002/4885PKM 4241/4885 |
| US-20140005196-A1 | METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION COMPRISING ADMINISTERING A TRIARYLMETHYL AMINE COMPOUND | APOB, APOL1, LDLR | MEN1 3242/4885KMT2A 797/4885PKM 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.